|1.||Andreeva, Elena N: 2 articles (09/2010 - 02/2008)|
|2.||Grodnitskaya, Elena E: 2 articles (09/2010 - 02/2008)|
|3.||Grigoryan, Olga R: 2 articles (09/2010 - 02/2008)|
|4.||Melnichenko, Galina A: 2 articles (09/2010 - 02/2008)|
|5.||Myers, Robert S: 1 article (08/2015)|
|6.||Matarasso, Alan: 1 article (08/2015)|
|7.||Paresi, Robert J: 1 article (08/2015)|
|8.||Huijbregts, Richard P H: 1 article (04/2015)|
|9.||Michel, Katherine G: 1 article (04/2015)|
|10.||Hel, Zdenek: 1 article (04/2015)|
03/01/2010 - "Most women note a beneficial effect on bleeding profiles and are satisfied with NuvaRing. "
09/01/2006 - "Intended bleeding was significantly better for all cycles with NuvaRing (55.2-68.5%) than that with the COC (35.6-56.6%) (P < 0.01). "
12/01/2002 - "Significantly more women using NuvaRing experienced an ideal 'intended bleeding pattern' compared with COC users at every cycle. "
12/01/2002 - "Irregular bleeding occurred in < 5% of all cycles with NuvaRing and between 5.4% and 38.8% per cycle with the COC. "
03/01/2002 - "Furthermore, the incidence of a normal intended bleeding pattern was significantly higher in the NuvaRing groups than in the combined oral contraceptive groups (P <.01). "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
08/01/2015 - "These patients developed deep venous thrombosis and pulmonary emboli in the postoperative period while using Nuvaring. "
04/01/2012 - "Thus, emergency physicians should suspect serious venous thromboembolic events, including CVST, deep venous thrombosis, and pulmonary embolism, in NuvaRing users in the proper clinical setting."
09/01/2006 - "Breakthrough bleeding or spotting during cycles 2-13 was in general less frequent with NuvaRing than that with the COC (4.7-10.4%) and showed a statistically significant odds ratio of 0.61 (95% confidence interval: 0.46, 0.80) with longitudinal analysis. "
08/01/2011 - "Breakthrough bleeding occurred in 11.3% of women receiving NuvaRing and in 14.7% of women receiving the COC; 2.1% and 2.9% of women, respectively, had no withdrawal bleeding. "
04/01/2012 - "We describe the case of a NuvaRing user who presented to our emergency department with a headache, who was diagnosed with CVST. "
04/01/2008 - "Contraceptive efficacy was high showing no significant differences in comparison with the COC; cycle control was good and consistently better than that of the COC; compliance was high and comparable with that of the pill; the incidence of adverse events such as breast tenderness, headache, and nausea was low, but not lower than with the COC despite a halving of the systemic exposure to ethinyl estradiol (EE) with NuvaRing compared with a 30-mug EE-containing COC; the incidence of local and ring-related events was low but higher than with the COC, leading to higher discontinuation rates among NuvaRing users; acceptability was high and comparable between both contraceptives, resulting in a global improvement of sexual function with both methods. "
|3.||Ethinyl Estradiol (Estinyl)
|5.||Contraceptive Agents (Contraceptives)
|1.||Female Contraceptive Devices (Vaginal Ring)
|2.||Contraception (Birth Control)
|3.||Transplantation (Transplant Recipients)